Vaginal Estrogen
genericFDA-approved; multiple branded and generic vaginal estrogen products available
Cost information
$15 - $100/mo depending on product and insurance
Vaginal estrogen is FDA-approved estradiol placed in the vagina as a small insert (Vagifem, Imvexxy), a 90-day ring (Estring) or a cream, to treat the dryness, burning and painful sex that come from vaginal atrophy after menopause. It is a different decision from systemic HRT: the doses are low, the labels are written for vaginal symptoms only, and telehealth services such as Alloy, Evernow and Midi Health list it among the treatments their clinicians can prescribe. Below are the labeled schedules, the trial results printed on each label, who should not use it, and what it costs to get online.
Dosage Format
Available as vaginal tablets (typically 10mcg inserted 2x/week after initial loading), vaginal cream (applied 2-3x/week as directed), vaginal ring (inserted every 3 months), or vaginal inserts. Dosing varies by product and is determined by a provider based on symptom severity.
Type
Generic
Who to discuss it with
Women experiencing vaginal dryness, painful intercourse, urinary symptoms, or vaginal atrophy who may prefer localized treatment over systemic HRT
Key distinction
Vaginal estrogen delivers very low doses of estrogen directly to vaginal tissues with minimal systemic absorption, which may make it suitable for some women who cannot take systemic HRT.
Updated · By Treatment Comparison Editorial Team · Sources and scope
Sources: DailyMed (NLM): Vagifem label · DailyMed (NLM): Imvexxy label · DailyMed (NLM): Estradiol cream label · Pfizer Medical Information: Estring label · MedlinePlus: MedlinePlus: vaginal estrogen · Menopause (journal), via Europe PMC: Menopause Society 2020 GSM statement · FDA: FDA February 2026 label changes
The four labeled forms side by side
| Product | Form and strength | Labeled schedule | Labeled use |
|---|---|---|---|
| Vagifem | Vaginal insert, 10 mcg estradiol | 1 daily for 2 weeks, then 1 twice weekly | Atrophic vaginitis due to menopause |
| Imvexxy | Vaginal insert, 4 mcg or 10 mcg | 1 daily for 2 weeks, then 1 twice weekly | Moderate to severe painful sex from vulvar and vaginal atrophy |
| Estring | Ring, 2 mg, releases about 7.5 mcg/day | Left in for 90 days, then replaced | Moderate to severe symptoms of vulvar and vaginal atrophy |
| Estradiol cream 0.01% | 0.1 mg estradiol per gram | 2 to 4 g daily for 1 to 2 weeks, then reduced; maintenance 1 g one to three times a week | Moderate to severe symptoms of vulvar and vaginal atrophy |
Sources: DailyMed (NLM): Vagifem label · DailyMed (NLM): Imvexxy label · DailyMed (NLM): Estradiol cream label · Pfizer Medical Information: Estring label
What the trials on the labels found
Vagifem 10 mcg was tested in a 12-month, double-blind trial of 309 postmenopausal women aged 46 to 81. At week 12 the most bothersome symptom score fell by 1.20 points with Vagifem and 0.84 with placebo, and vaginal pH and the share of superficial cells also improved more than with placebo.
Imvexxy was tested in a 12-week trial of 574 postmenopausal women aged 40 to 75. Pain-with-sex severity fell by 1.52 points with 4 mcg, 1.69 with 10 mcg and 1.28 with placebo; both strengths were statistically better than placebo. Note that placebo groups also improved, so the difference between groups is the fair measure.
Sources: DailyMed (NLM): Vagifem label · DailyMed (NLM): Imvexxy label
The uterus question
Systemic estrogen alone raises the risk of endometrial cancer in women with a uterus, which is why systemic HRT pairs it with a progestogen. For low-dose vaginal estrogen, the Menopause Society says a progestogen is not indicated, but also that endometrial safety has not been studied in trials beyond 1 year. In Vagifem's 12-month trial, end-of-study biopsies in 172 women found one endometrial cancer and one case of hyperplasia without atypia. Unexpected bleeding on any of these products should be reported and checked.
Sources: DailyMed (NLM): Vagifem label · Menopause (journal), via Europe PMC: Menopause Society 2020 GSM statement
Boxed warnings after the 2026 FDA changes
FDA announced on February 12, 2026 that it had approved labeling changes for a first group of six hormone therapy products, including at least one topical vaginal estrogen, removing cardiovascular disease, breast cancer and probable dementia statements from the boxed warning. Pfizer's Estring information, revised April 2026, now lists those risks in its warnings section rather than a boxed warning. The Vagifem, Imvexxy and generic estradiol cream labels we opened on DailyMed still carry the four-part boxed warning. More labels may change, so check the version for your product.
Sources: DailyMed (NLM): Vagifem label · DailyMed (NLM): Imvexxy label · DailyMed (NLM): Estradiol cream label · Pfizer Medical Information: Estring label · FDA: FDA February 2026 label changes
Getting it online and what it costs
Alloy lists estradiol vaginal cream at $119.97 for a 3-month supply, serves all 50 states and D.C., and describes itself as cash-pay with FSA/HSA cards accepted. Evernow's membership starts at $35 per month, and it can send prescriptions to your pharmacy, so the medicine price depends on where it is filled and your coverage. Midi Health is in-network with most major insurers; copays and deductibles may still apply. Ask each service whether its cream is an FDA-approved product or compounded, and confirm the ongoing total before you pay.
Sources: Alloy: Alloy solutions · Alloy: Alloy · Evernow: Evernow · Midi Health: Midi Health
Where to Get Vaginal Estrogen
Provider listings related to vaginal estrogen. Confirm the exact formulation, current availability, and full price directly.
Alloy Health
Alloy's solutions page lists estradiol vaginal cream as a 3-month supply and a Sexual Health Bundle with its O-mazing cream at $168.97 per 3 months. Alloy says it serves all 50 states and D.C., is cash-pay and accepts FSA/HSA cards. The page does not say whether the cream is an FDA-approved product or compounded, so ask before you order.
Estradiol vaginal cream $119.97 per 3-month supply
Evernow
Evernow's homepage promotes a vaginal estrogen cream and says it can send medication to your pharmacy or arrange home delivery. It says it accepts insurance for video visits; it does not say whether insurance covers the medicine.
Membership from $35/month; medicine cost depends on the pharmacy
Midi Health
Midi says it is in-network with most major insurers, that deductibles, coinsurance and copays may still apply, and that it is available in all 50 states. Vaginal estrogen appears among the care-plan options for dryness.
Insurance or self-pay; self-pay prices not shown on the homepage
Gennev
Gennev's website could not be opened when we checked on October 26, 2026, so we cannot confirm its current vaginal estrogen offer or prices. Check with Gennev directly.
Not confirmed
How Vaginal Estrogen Works
After menopause, lower estrogen levels thin the vaginal lining and reduce moisture, which the Menopause Society calls genitourinary syndrome of menopause (GSM). Estradiol placed in the vagina acts directly on that tissue. In the Vagifem trial, the share of mature superficial cells in the vaginal lining rose and vaginal pH fell compared with placebo, both signs that the tissue was responding. The labels still describe some estradiol reaching the bloodstream, which is why the same warnings and contraindications that apply to estrogen appear on vaginal products.
Side Effects
Common
- • Vaginal yeast infection (8% with Vagifem vs 3% with placebo in its 12-month trial)
- • Vaginal itching (8% vs 2% in the same trial)
- • Back pain and diarrhea (7% and 5% with Vagifem in that trial)
- • Headache (the most common reaction reported with Imvexxy)
- • Vaginal discharge, breast tenderness, bloating or nausea (listed by MedlinePlus)
Serious risks and warning signs
- • Any unexpected vaginal bleeding: the labels say it needs evaluation
- • Signs of a blood clot: leg or arm swelling, pain or warmth, sudden shortness of breath or chest pain
- • Stroke symptoms, sudden vision changes or a severe headache
- • Allergic reaction such as hives, rash or trouble breathing
Eligibility to Discuss With a Clinician
The labels list who should not use vaginal estradiol: undiagnosed abnormal genital bleeding, current or past breast cancer or another estrogen-dependent cancer, a current or past blood clot in the legs or lungs, a past stroke or heart attack, liver disease, a known clotting disorder (protein C, protein S or antithrombin deficiency), or an allergic reaction to the product. If you have had breast cancer, the Menopause Society says there are not enough data to confirm safety and that treatment should consider your oncologist's recommendations. A clinician decides whether it fits your history.
Related Medications
Provider Reviews
Explore providers in the menopause / hrt category. This does not mean every provider offers Vaginal Estrogen; check the exact product with the provider.
Related Articles
Frequently Asked Questions
Sources and editorial notes
Medicine facts and trial numbers come from the Vagifem, Imvexxy and estradiol vaginal cream labels on DailyMed, Pfizer's Estring prescribing information, MedlinePlus, FDA and the Menopause Society's 2020 GSM position statement, checked on 2026-10-26. Prices come from Alloy's, Evernow's and Midi Health's public pages that day; Gennev's site could not be opened. We did not order or verify a personalized price. No clinician review is claimed.
Content updated . Source checking is editorial work; it is not a clinical review.
- DailyMed (NLM): Vagifem (estradiol vaginal inserts) prescribing informationMedical or regulatory reference · Accessed 2026-10-26
- DailyMed (NLM): Imvexxy (estradiol vaginal inserts) prescribing informationMedical or regulatory reference · Accessed 2026-10-26
- DailyMed (NLM): Estradiol Vaginal Cream USP 0.01% prescribing informationMedical or regulatory reference · Accessed 2026-10-26
- Pfizer Medical Information: Estring (estradiol vaginal ring) prescribing informationMedical or regulatory reference · Accessed 2026-10-26
- MedlinePlus: Estrogen (Vaginal Route)Medical or regulatory reference · Accessed 2026-10-26
- Menopause (journal), via Europe PMC: The 2020 genitourinary syndrome of menopause position statement of The North American Menopause SocietyMedical or regulatory reference · Accessed 2026-10-26
- FDA: FDA approves labeling changes for menopausal hormone therapy productsMedical or regulatory reference · Accessed 2026-10-26
- Alloy: Alloy solutions and pricesProvider-reported product information · Accessed 2026-10-26
- Alloy: Alloy menopause careProvider-reported product information · Accessed 2026-10-26
- Evernow: Evernow menopause careProvider-reported product information · Accessed 2026-10-26
- Midi Health: Midi Health menopause careProvider-reported product information · Accessed 2026-10-26